# Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

> **NCT00604175** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 319 (actual)

## Conditions studied

- HIV Infections
- Sexually Transmitted Diseases

## Interventions

- **BIOLOGICAL:** Quadrivalent HPV vaccine

## Key facts

- **NCT ID:** NCT00604175
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-11
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604175, "Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00604175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*